Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal Tenofovir Disoproxil Fumarate to prevent mother-to-child transmission of hepatitis B virus /Salvadori, Nicolas Fan, B. Teeyasoontranon, W. /Ngo-Giang-Huong, Nicole /Cressey, Tim /Decker, Luc /Jourdain, Gonzague et al. In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. 2019 text https://www.documentation.ird.fr/hor/fdi:010076467 fdi:010076467 Salvadori Nicolas, Fan B., Teeyasoontranon W., Ngo-Giang-Huong Nicole, Cressey Tim, Decker Luc, Jourdain Gonzague, et al.. Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal Tenofovir Disoproxil Fumarate to prevent mother-to-child transmission of hepatitis B virus. 2019, 69 (1), 144-146 EN THAILANDE